A drug–gene interaction occurs when a patient's genetic CYP450 type (e.g., CYP2D6 poor metabolizer) affects that patient's ability to clear a drug. A drug–drug–gene interaction occurs when ...

Genetic testing is transforming depression treatment by tailoring antidepressants to your DNA for better results and fewer ...

Authors: Siphokazi Tshoko, Yonela Mgwili, Siphamandla Nqunqa, Takalani Mulaudzi, Noluthando Mayedwa, Emmanuel Iwuoha Email ...

“Based on our preliminary data, we estimate that DNA testing could reduce adverse drug reactions by 30%, saving the NHS up to ...

Supplemental New Drug Application (sNDA) submission anticipated in 3Q 2025 ...

New Analyses Related to Aficamten Expand on its Metabolism Pathways,Treatment Effect Associated with Combination Therapy with Disopyramideand ...

Cytokinetics (CYTK) announced five presentations related to aficamten, an investigational cardiac myosin inhibitor, and hypertrophic ...

Concomitant strong CYP3A4 or CYP2D6 inhibitors ... Adjust dose to normal range when these drugs are withdrawn. Other dose adjustments: see full labeling.

Medications changed by the liver (Cytochrome P450 2D6 (CYP2D6) substrates) interacts with QUERCETIN Some medications are changed and broken down by the liver. Quercetin might change how quickly ...

Interactions With Drugs Metabolized by CYP2D6: Use caution when administering IMKELDI with CYP2D6 substrates where minimal concentration changes may lead to serious adverse reactions. Imatinib is a ...